Atlas Trials

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Clinical trial NCT04234113 · TERMINATED

Trial details

NCT number
NCT04234113
Sponsor
SOTIO Biotech AG
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Thyroid CancerRenal Cell CarcinomaNon Small Cell Lung CancerSmall-cell Lung CancerBladder CancerMelanomaMerkel Cell CarcinomaSkin Squamous Cell CarcinomaMicrosatellite Instability HighTriple Negative Breast CancerMesotheliomaThymic Cancer
Start date
2019-06-13
Primary completion
2024-08-31
Enrollment
115

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.